Brought to you by 
Bionomics enters US through Eclipse Therapeutics acquisition
21 Sep 2012
Executive Summary
Australian cancer, immune, and CNS drug developer Bionomics Ltd. has acquired privately held US-based Eclipse Therapeutics Inc. (developing drugs that target cancer stem cells). Bionomics issued 23.9mm of its shares, valued at $7.9mm, giving Eclipse shareholders a 6.5% stake in Bionomics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bionomics enters US through Eclipse Therapeutics acquisition
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice